Polar Capital LLP Grows Position in Pacira Pharmaceuticals Inc (PCRX)

Polar Capital LLP boosted its holdings in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 113.0% in the 4th quarter, Holdings Channel reports. The firm owned 600,425 shares of the company’s stock after purchasing an additional 318,601 shares during the period. Polar Capital LLP’s holdings in Pacira Pharmaceuticals were worth $25,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Pacira Pharmaceuticals by 7.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after purchasing an additional 243,213 shares during the last quarter. Vanguard Group Inc raised its position in Pacira Pharmaceuticals by 7.2% in the 3rd quarter. Vanguard Group Inc now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after purchasing an additional 243,213 shares during the last quarter. Man Group plc raised its position in Pacira Pharmaceuticals by 258.0% in the 3rd quarter. Man Group plc now owns 45,817 shares of the company’s stock valued at $2,251,000 after purchasing an additional 33,018 shares during the last quarter. Timpani Capital Management LLC purchased a new stake in Pacira Pharmaceuticals in the 4th quarter valued at $2,375,000. Finally, Morgan Stanley raised its position in Pacira Pharmaceuticals by 153.4% in the 3rd quarter. Morgan Stanley now owns 275,769 shares of the company’s stock valued at $13,554,000 after purchasing an additional 166,933 shares during the last quarter.

NASDAQ:PCRX opened at $38.73 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 7.08 and a current ratio of 7.88. Pacira Pharmaceuticals Inc has a fifty-two week low of $26.95 and a fifty-two week high of $55.00. The firm has a market cap of $1.55 billion, a PE ratio of 133.55, a P/E/G ratio of 2.37 and a beta of 1.49.



Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, February 28th. The company reported $0.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.40. Pacira Pharmaceuticals had a negative net margin of 0.14% and a positive return on equity of 3.94%. The business had revenue of $95.12 million for the quarter, compared to analysts’ expectations of $93.69 million. During the same period in the prior year, the company posted $0.38 EPS. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. As a group, equities research analysts expect that Pacira Pharmaceuticals Inc will post 0.66 earnings per share for the current fiscal year.

In related news, Director Mark A. Kronenfeld purchased 1,700 shares of the stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of $38.97 per share, with a total value of $66,249.00. Following the purchase, the director now directly owns 9,277 shares in the company, valued at approximately $361,524.69. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Several analysts recently commented on the stock. Cowen reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday, March 1st. Stifel Nicolaus reiterated a “sell” rating and issued a $33.00 price target on shares of Pacira Pharmaceuticals in a research report on Friday, March 8th. BMO Capital Markets set a $44.00 price target on shares of Pacira Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, March 1st. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 20th. Finally, National Securities began coverage on shares of Pacira Pharmaceuticals in a research report on Tuesday, February 12th. They set a “sell” rating for the company. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $53.25.

WARNING: This piece was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://dakotafinancialnews.com/2019/03/14/polar-capital-llp-grows-position-in-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Story: What does RSI mean?

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply